(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs ...

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor ...

Matchpoint Therapeutics said that it has signed an exclusive option and license agreement with Novartis (NYSE:NVS) to develop ...

Avalere Health, a 2025 MM+M Agency 100 honoree, named Rhiannon Meaden, PhD, as head of medical strategy and transformation.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

A roundup of global health news reveals rising challenges, including Brazil's bird flu outbreak, vaccine policy changes by ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis made one of the biggest investments in Cannes among pharma companies, sending approximately 20 people from the ...

Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the ...